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Antibiotic resistance is becoming ever more severe due in part to the increasing use of
antibiotic drugs. One significant contributor to this problem is the production of β-
lactamase enzymes that provide resistance to common β-lactam antibiotics such as
penicillin. The scope of this research is to synthesize and study the β-lactamase inhibitors
of 2-carbamoyl-4-oxo-1, 5-diazabicyclo [3.2.1] octane derivatives. β -lactamase inhibitors
can inhibit the biological function of bacterial β-lactam and aid in the prevention of
hydrolysis. Currently the research process is in the beginning stages of synthesizing three
compounds: (R)-hexahydro-6-oxopyrimidine-4-carboxylic acid (1a),
Based on molecular structures and amino acid sequences, β-lacamase can be divided into four
classes: A, B, C, and D. Class A, C and D are serine enzymes acyl intermediate are produced at
the active site during hydrolysis. In Class B, one or two zinc ions are required at the active site
to maintain related biological functions.1
Class A (e.g. SHV, CTX-M, and SSHV) are broad-spectrum β-lactamases and mainly
hydrolyze carbapenems such as cephalosporins, aztreonam, and penicillin. The general
mechanism is Lys or Glu activation by water followed by nucleophilic attack on carbonyl
carbon in lactam ring by serine.2 As a result acyl-enzyme intermediate is produced.
Clavulanate acid, sulbactam, and tazobactam can form stable covalent complexes and bind to
enzyme irreversibly, which results in loss of the activity and function of class A lactamases.
Class C lactamases (e.g. AmpC) which are encoded by bla genes on the chromosome are
important enzymes in clinical diagnostics. AmpC lactamases are sensitive to oxacillin,
aztreonam and cloxacillin, but are typically resistant to cephamycins, cephalosporins and
penicillin. Tyr150 can activate Ser64 by attacking lactam ring in a hydrolysis process as general
base.
Class D lactamases Ser67 in the chromosome sequences is activated for acylation by
carboxylate Lys70 which serves as a general base during nucleophilic attack of lactam ring.
Oxacillin, aztreonam and cloxacillin are typical antibiotics used to inhibit biological function
and activity of Class C lactamases.3 However, other most commonly used antibiotics such as
cephamycins, cephalosporins and pencilicins show no effect in inhibiting activity of Class C
enzymes. Some other inhibitors only can work when the enzymes are at low level, such as
sulbactam, clavulanic acid and tazobactam.
Class B lactamases are zinc ion dependent which is unique as compared with previous types
of enzymes and their molecular structures are in a triangular shape. It can be divided into
three subclasses based on zinc binding motifs, which are B1 (Zinc 1 ligands at His 116-His
118-His 119 and Zinc 2 ligands at Asp 120-Cys 221-His 263), B2 (Asn116-His118-His196 and
Zinc 2 ligands at Asp 120-Cys221-His263), and B3 (Zinc1ligands at His116-His 118-196 and
Zinc 2 ligands at Asp120-His121-His263).4 Clinical research reveals that hydroxide ion
located between zinc ions performs nucleophilic attack during hydrolysis and intermediate
formed is stabilized by zinc ions. Protonation of nitrogen atom is the next step in hydrolysis.
No effective antibiotics has been found to inhibit the activity of Class B since these type
enzyme can catalyze hydrolysis of a wide range of lactams molecule.5
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EXPERIMENTAL PROCEDURE
Scheme 1: Synthetic route of  compound(1a),hexahydro-6-oxopyrimidine-4-carboxylic acid, 
compound(1b),hexahydro-2,2-dimethyl-6-oxopyrimidine-4-carboxylic acid and compound(1c),hexahydro-6-
oxo-2-phenylpyrimidine-4-carboxylic acid.
N N
O
H 2 N
O R
hexahydro-2,2-dimethyl-6-oxopyrimidine-4-carboxylic acid (1b)
and hexahydro-6-oxo-2-phenylpyrimidine-4-carboxylic acid (1c).
The future steps are to synthesize (R)-3-(methoxycarbonyl)-
hexahydro-6-oxopyrimidine-4-carboxylic acid (2a), (R)-dimethyl
tetrahydro-4-oxopyrimidine-1,6(2H)-dicarboxylate (3a) and (R)-
methyl hexahydro-6-oxopyrimidine-4-carboxylate (4a).
Compound 1a: To a solution of  D-asparagine(30.1526 g) in 400 mL water at 45 °C, add 16.25 mL of  37% 
formaldehyde. After stirring for 10 hours at 45°C the solution was cooled down to -5°C to give a white slurry. 
The slurry was allowed to warm up 0°C, then the precipitate collected by vacuum filtration. The compound 
then put into oven to dry for over night.
Compound 1b: To a mixture of  D-asparagine(1.2 g, 8 mmol) in HPLC grade acetone(12 mL), KOH solid 
(0.55 g, 8 mmol) was added into. The reaction set at oil bath at 120 °C, then do reflux for 10 hours, magnetic 
stirring rate set at 400 rpm.
Compound 1c: Obtain 1.5 g (10 mmol) D-asparagine monohydrate, dissolve in 30 mL methanol and input 
0.68 g (20 mmol) potassium hydroxide, then add 1.43 mL benzyaldehyde dropwise, and the reaction mixture 
was kept at 25 °C for 12 hours. Then add 10 mL ether to the reaction flaks to wash and filtrate to obtain white 
sold.
Retrosynthetic analysis:
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CONCLUSION
We have synthesized several compounds (1 a-c) and we are currently in the process of
producing 1a derivatives (2a, 3a, and 4a). All chemical structures were characterized based on
1H- and 13C-NMR spectra. We will continue our multistep synthetic pathway to make the
target compound. The biological activity of all compounds will be tested in our lab or in
collaboration with other research groups. The focus of our bioassay will be on antibacterial
potency or/and inhibitory activity against class A and C serine b-lactamases.
